Navigation Links
Positive Trial Results, Completed Acquisitions, and Clearances - Research Report on Dyax, IPC, Array BioPharma, Lexicon Pharmaceuticals, and Wright Medical
Date:12/20/2013

e inhibitors in patients with multiple myeloma at the 2013 Annual Meeting of the American Society of Hematology. Michael Needle, MD, Chief Medical Officer of Array BioPharma, stated, "Multiple myeloma remains an incurable disease, with a significant unmet medical need in patients who are relapsed/refractory to IMiDs and proteasome inhibitors. Filanesib is a first-in class drug in myeloma that is well tolerated and has shown very encouraging clinical activity in heavily pretreated patients who have limited therapeutic options. Furthermore, we are excited about the potential of our patient selection marker, AAG, which should help us identify which patients have the best chance to benefit from receiving filanesib." The Full Research Report on Array BioPharma Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e048_ARRY

--

Lexicon Pharmaceuticals, Inc. Research Report

On December 3, 2013, Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). The Company informed that the primary endpoint of this study was the change in stool consistency averaged from baseline to day 28. Pablo Lapuerta, M.D., Chief Medical Officer of Lexicon Pharmaceuticals, stated, "While LX1033 showed similar improvements in stool consistency as compared to the placebo patients who completed the study, there were positive effects on abdominal pain in the treated group that warrant further study. While this initial Phase 2a study was underway, we completed long-term toxicology studies that would allow us to conduct a Phase 2b study at doses informed by the current results and with
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
2. According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients
3. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
4. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
5. Upsher-Smith Debuts Positive Results From Global Phase 3 Study Evaluating USL255 (extended-release topiramate) In Epilepsy Patients With Refractory Partial-Onset Seizures
6. Annual General Meeting Schedules, New Drug Applications, Positive Study Results, Conference Participations, and Secondary Offerings - Research Report on Mindray, AcelRx, Merrimack, ZELTIQ, and Clovis
7. Dividends, Recognitions, Positive Opinions, Share Repurchase Programs, and Award Programs - Research Report on BD, Sanofi, GSK, Agilent Technologies, and Align Technology
8. According to Surveyed EU5 Oncologists, Zelboraf Captures 50 Percent Patient Share of the First-Line BRAF-Mutation Positive Malignant Melanoma Population
9. Positive FDA Meeting Confirms BDSI Phase 3 Program for Clonidine Topical Gel for Treatment of Painful Diabetic Neuropathy
10. Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer
11. According to Surveyed U.S. Oncologists, Zelboraf is the Patient Share Leader in First-Line BRAF-Mutation Positive Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today ... given the company permission to conduct an open-label study ... months of age with a diffuse intrinsic brainstem glioma ... five treatment groups based on their age and whether ... The primary study endpoint is a decrease in the ...
(Date:10/22/2014)... , Oct. 22, 2014  Rescheduling of ... transformation in the pain market, according to a ... Inc., a firm providing market research and consultation ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... change for hydrocodone combination products from Schedule III ...
(Date:10/22/2014)... Oct. 22, 2014   Reproductive Medicine Associates ... in the field of infertility, presents new clinical ... screening. The research abstract, released during the 70 ... (ASRM) meeting in Honolulu, Hawaii ... gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... UPI ), a medical device company that develops, ... announced today that David Kaysen, President and CEO, and Medi ... strategy and financial results at the Sixth Annual JMP Securities ... 2011 at The St. Regis Hotel in New York. ...
... Reportlinker.com announces that a new market research report is ... The Global Market http://www.reportlinker.com/p0619259/Generic-Drugs-The-Global-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Generic_Drug ... The global generics market is estimated at about $225 ... the value of the total global generics sector will ...
Cached Medicine Technology:Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference 2Generic Drugs: The Global Market 2Generic Drugs: The Global Market 3Generic Drugs: The Global Market 4Generic Drugs: The Global Market 5Generic Drugs: The Global Market 6Generic Drugs: The Global Market 7Generic Drugs: The Global Market 8Generic Drugs: The Global Market 9Generic Drugs: The Global Market 10Generic Drugs: The Global Market 11Generic Drugs: The Global Market 12
(Date:10/25/2014)... 2014 Background: , In 1998 Bob ... is a pioneer in the field of establishing recovery community ... treatment system and when he retired, he set out to ... public service. , 1. Where are the ... them? , 2. Can the recovery community be organized ...
(Date:10/25/2014)... October 25, 2014 QueenBeeTickets.com has a ... great selection at affordable prices. Bob Seger & The ... Center and Nationwide Arena are going on sale October ... Click Here to browse the selection of tickets ... QueenBeeTickets.com. , The famous singer is touring North America ...
(Date:10/25/2014)... CT (PRWEB) October 25, 2014 Limbkeepers® ... upcoming episode of Innovations with Ed Begley Jr, airing ... times TBA. , In this episode, Innovations will focus ... helping to protect fragile, thinning skin on arms, hands, ... will learn about these versatile products, which help reduce ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- Researchers who discovered ... findings are cause for concern. The use ... raised for human consumption contribute to the development ... to background information from the study. Each ... about 2 million people and kill about 23,000, ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... ... ‘Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery’. ... ... of laser, light-based and radiofrequency devices for surgical, aesthetic, and ophthalmic applications, announced ...
... fewer attacks per year, save millions in health costs, ... If all states banned smoking in restaurants, offices and ... from heart attacks would drop by more than 18,000 ... bans have been implemented in some states, but not ...
... explanation for the difference, study says , THURSDAY, May ... common form of stroke has decreased significantly among whites ... new regional survey designed to be representative of the ... Greater Cincinnati/Northern Kentucky Stroke Study showed an overall drop ...
... from The University of Texas MD Anderson Children,s Cancer Hospital ... patients increased the survival of children with rare tumors in ... issue of the Journal of Pediatric Surgery , looked ... aggressive pediatric cancer known as desmoplastic small round cell tumor ...
... Montreal, May 20, 2010 The results of a ... by Dr. Jean-Claude Tardif are now available in the journal ... of the MHI Research Centre, as well as a professor in ... at the Universit de Montral. The promising findings of ...
... ... Association (NRPA) is reminding Americans to take the proper steps to ensure that their local ... Dirty Dozen, a comprehensive brochure and playground-safety resource for playground managers, parents and caregivers. ... Ashburn, VA (Vocus) May ...
Cached Medicine News:Health News:Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery' 2Health News:Lumenis Announced Today it is Sponsoring the Endometriosis Foundation of America's Symposium 'Advancing the Art and Science of Endometriosis: Stem Cells to Radical Excision Surgery' 3Health News:Big Decline in Heart Attacks If All States Had Smoking Bans 2Health News:Stroke Incidence Down, But Not for Blacks 2Health News:Surgical procedure offers new option for pediatric patients with rare cancer in abdomen 2Health News:Surgical procedure offers new option for pediatric patients with rare cancer in abdomen 3Health News:Patients at high risk of recurrences of heart disease: Breakthrough in prevention 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 2Health News:Spring into Summer with The Dirty Dozen Guide to Playground Safety 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: